To compare the safety and antidepressant efficacy of paroxetine, imipramine, and placebo, data from six centres using the same protocol were pooled. A double-blind parallel.group design was used, with therapy lasting six weeks. From week 2 onwards, both the 240 paroxetine-treated and the 237 imipramine-treated patients were significantly different from the 240 placebo-treated patients, but no different from each other. Side-effects with paroxetine were less likely to lead to drop-out than with imipramine. Paroxetine had a possible earlier antidepressant effect than imipramine,anda possibleearlierbeneficial effect on anxietysymptomsassociatedwith depression.
Paroxetine is a potent and selective inhibitor of serotomn (5-HT) uptake. This effect has been demonstrated both in animal studies (Thomas et al, 1987) and with human platelets (Marsden, 1987; Raptopoulus et a!, 1989) . Pharmacological electro encephalography (EEG) and sleep EEG studies in animals (Johnson, 1989) and volunteers (McClelland & Raptopoulus, 1984; McClelland et al, 1989 ) indicate a non-sedating profile associated with features typical of an antidepressant. Paroxetine has no effect on psychomotor skills when given alone nor when administered with other depressants of the central nervous system (CNS) including alcohol, oxazepam, amylobarbitone and haloperidol (Cooper etal, 1989) . Metabolism ofparoxetine occurs inthe liver, there being a large first-pass effect (Kaye et al, 1989) . Metabolism is dose-dependent to some extent (Kaye et al, 1989) , producing wealdy active meta bolites which do not compromise the selectivity of paroxetine for 5-HT systems (Haddock et al, 1989) , and probably do not contribute to paroxetine's therapeutic effect. Plasma elimination half-life is on average 24 hours, but marked inter-individual variability is seen. Once steady state is reached, further accumulation does not occur. The present study was undertaken to determine the efficacy and safety of paroxetine as an antidepressant.
Method
A double-blind randomised parallel-group protocol was used in sixstand-alone centresin the USA, during which paroxetine was compared with imipramine and placebo. Patients aged 18-65 years who metDSM-IIIcriteria (American Psychiatric Association, 1980) fora majordepressive episode were recruited on an out-patient basis. All subjects had a score on the Hamilton Rating Scale for Depression (HRSD; Hamilton, 1960) of @ 18 on the first 17 items at baseline, and a Raskin depression score greater than the Covi anxiety rating (Raskin ci al, 1969; Covi eta!, 1981) .Therapy lasted six weeks following a placebo run-in period of 4â€"14 days.
Any patients who had a reduction )20'Fo in the HRSD score over this period were excluded. This procedure eliminated patients with a rapid response to placebo and thus helped heighten drug/placebo differences. The remaining subjects were randomised to paroxetine, imipramine or placebo. Paraoxetine therapy started at 20mg; after one week the dose could be adjusted in the range 10â€"30 mg. A week later further adjustment in the range 10â€"40mg could be made, and during weeks 4â€"6 the dose was in the range 10-50 mg. Dose alteration depended on clinical response and tolerability. Imipramine therapy started with 80 mg. This was adjusted in the range 65â€"145mg for week 2, 65â€"210mgfor week 3 and 65-275 mg for weeks 4-6. The following rating scales were completed at screening, at baseline, and at 1, 2, 3, 4 and 6 weeks: HRSD; clinical global impression -severity of illness(CO!); Montgomery-Asberg Depression Rating Scale (MADRS; Montgomery & Asberg, 1979); Covi Anxiety Rating Scale; and patient global experienee (POE). Tolera bility was assessed by asking a non-leading question. Spon taneous responses were recorded, as were all clinical adverse events. Safety was assessedby means of full haemaxological, biochemical and urine analysis at baseline and at 3 and 6 weeks. Chest X-ray (CXR) and electrocardio-gram (ECO) were recorded at baseline and end of therapy. Compliance was assessed by means of a capsule count at each visit.
Data-handling and statistics
A combined analysis was undertaken using pooled data from all six centres. Results from one centre have already been published (Feighner & Boyer, 1989) . The primary outcome variable was the HRSD total score, but the following efficacy variables were also considered: HRSD factors, anxiety-somatisation,cognitive disturbance, retardation, sleep disturbance, COl, MADRS total score, Covi, and POE
rating. An intention-to-treat analysis was performed using all subjects, who were randomised and subsequently used an extender or last observation carried forward (LOCF) data set. The visit-baseline change score was used in the appropriate statistical model. This was usually a one-way analysis of variance or Fisher's exact test. The end of week 6 was considered the primary time point for all efficacy variables. However, data for other week assessmentsare given. The intention-to-treat sample was used in all safety and tolerability assessments. Adverse events were coded, using COSTART (Food and Drug Administration, 1989) , by body system and preferred term. Laboratory safety data and vital signs were assessed using both group mean changes and outlier-flagging techniques. Values that fell outside a predetermined extended normal range were identified.
Results
There were 241 patients randomised to paroxetine treatment, 240 of whom were entered into the intention-to-treat analysis and 214 into the efficacy analysis. Respective The reasons for drop-out are given in Table 1 . When compared with the paroxetine and imipramine groups, significantly more patients treated with placebo were withdrawn from the study for lack of effect. In con trast, significantly more patients who received paroxetine or imipramine were withdrawn due to adverse events. Also, significantlymore imipramine-treatedpatients than paroxetine-treated patients dropped out due to adverse effects.
Results of the outcome variables are given in Table 2 .
Considering the total HRSD score, by 2 weeks both paroxetine-and imipramine-treated patients had improved significantly when compared with placebo-treated patients.
Table 1 Overviewof reasonsfor drop-outfrom intention-to-treat
This difference was maintained up to 6 weeks and was found on both the intention-to-treat and efficacy analyses.
Considering results on the factor scores of the HRSD scale, paroxetine improved retardation symptoms by 1 week and anxiety-somatisation symptoms by 2 weeks, when compared with placebo. Similar improvement due to imipramine occurred at 2 and 3 weeks respectively. Anxiety symptoms were significantly less frequent in paroxetine treated patients than in imipramine-treated patients at 2 weeks. Sleep symptoms were improved on paroxetine by 2 weeks and on imipramine by 3 weeks, when compared with placebo.
As to the other efficacy variables, paroxetine-treated patients were significantly different from placebo-treated subjects as measured on the MADRS at 1 week. This difference was found by 2 weeks for imipramine-treated patients.
On the Covi scale, anxiety symptoms were significantly less by 2 weeks in the paroxetine group than in the placebo group. A significant difference for imipramine-treated patients did not occur until 6 weeks.
TheCOIand POE resultsboth showedmoreimprovement in paroxetine-and imipramine-treated patients than in placebo subjects from 2 weeks onwards.
The frequencies with which patients reported adverse events are given in Table 3 . Both paroxetine and imipramine caused more adverse events and severe adverse events than placebo. Imipramine caused more adverse events and severe adverse events than paroxetine. The events in question are given in Table 4 . Many symptoms were caused by both active medications, but in general the symptoms experienced on imipramineweremore severethan on paroxetine, since the drop-out rates due to adverse events were 36Â°lo and 23% respectively (Table 1) .
Considering haematological, biochemical and urinary safety tests, no clinically significant changes were seen with either paroxetine or imipramine. Some results for paroxetine showed values different from placebo, but usually the change was more marked on imipramine. This was particularly the case for liver-function tests and pulse rate.
No clinically important differences were found with vital signs, ECG or CXR, for either paroxetine or imipramine, when compared with placebo.
Tablet count indicated compliance was similar in the three treatment groups.
Discussion
This study provided good evidence for the efficacy of paroxetine as an antidepressant. Change scores on the HRSD (total), MADRS, CGI and POE outcome variables showed significant differences between paroxetine and placebo and between unipramine and placebo from 2 weeks onwards. No difference was found between paroxetine and imipramine on any of these variables. These findings indicate that the antidepressant efficacy of paroxetine is similar to that of the standard tricydic comparator. Results on the efficacy rating scales were supported by drop-out 1. Fisher'sexacttest, paroxetine-placebo difference, P @O.001 -2. Fisher's exacttest,paroxetine-imipramine difference, P @O.OO1. 3. Fisher'sexacttest, imipramine-placebo difference, P @ 0.001.
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points. The possibility that it may have been a real effect,however, wassupported byresults ontheCovi anxiety scale: iniipramine treatment did not separate from placebo until 6 weeks on this direct measure of anxiety (Table 2) .
On the MADRS, paroxetine was superior to placebo at 1 week, whereas on the HRSD total score, superiority was seen only at 2 weeks. The fact that the MADRS is particularly sensitive for measuring change in depressed patients (Montgomery & Asberg, 1979) supports the argument that the early detection of this efficacy did not occur simply by chance.
In this trial, good agreement was found between the observer (CGI) and patient (POE) global rating scales from 2 weeks onwards. Often, CGI ratings record an improvement not reflected on the POE: the present accord perhaps adds credibility to the overall findings.
Paroxetine was clearly associated with a number of side-effects. Many of these were similar to those seen with imipramine, but others (nausea, yawning, delayed ejaculation) were more typical of this class of selective inhibitor of 5-HT uptake (Mas et a!, 1985; Renji, 1986; Okuyama eta!, 1987; Doogan & Caillard, 1988; Herman et a!, 1990 ).
Further differences were noted between paroxetine and imipramine. Thus, anticholinergic and cardio vascular features were more frequent with the tricyclic antidepressant, as were symjioms of excessive sedation. Overall, the side-effects of paroxetine were more benign than those of imipramine, since they were less severe (Table 3) and less likely to lead to drop-out (Table 1) .
